可吸收的微球同时提供HIF-1α抑制剂,通过逆转瘤缺氧和免疫抑制来增强跨动脉化学栓塞
Jiakun Guo1, Jintao Huang2, Yan Wang1
1Biomedical Polymers Laboratory, and Jiangsu Key Laboratory of Advanced Functional Polymer Materials, College of Chemistry, Chemical Engineering and Materials Science, and State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou 215123, China.
Acta biomaterialia
|March 9, 2026
概括
这项研究开发了可吸收的微球 (Asphere) 来同时提供化疗和晚期肝癌 (HCC) 的低氧抑制剂. 这种方法可以逆转瘤缺氧和免疫抑制,增强跨动脉化学栓塞 (TACE) 治疗的有效性.
科学领域:
- 在瘤学瘤学.
- 药物运输 药物运输 药物运输
- 生物材料是一种生物材料.
背景情况:
- 跨动脉化学栓塞 (TACE) 是对不可切除的肝细胞癌 (HCC) 的首要治疗方法.
- 瘤缺氧和免疫抑制限制了TACE在晚期HCC中的疗效.
- 需要新的药物输送系统来克服这些挑战.
研究的目的:
- 开发可吸收的微球 (Asphere),用于同时输送epirubicin (EPI) 和低氧诱导因子1 (HIF-1) 抑制剂acriflavine (ACF).
- 评估EPI/ACF装载的Aspheres (EA@Asphere) 在逆转瘤缺氧和促进TACE治疗晚期HCC的疗效.
主要方法:
- 阿斯菲尔在8周内显示了EPI和ACF的快速加载和持续释放.
- EA@Asphere抑制了低氧相关的蛋白质,并诱导了HCC细胞中的免疫细胞死亡.
- 临床前模型 (H22肝瘤,VX2肝瘤) 用于评估瘤回归,免疫反应和转移.
主要成果:
- EA@Asphere有效地逆转了瘤缺氧和免疫抑制.
- 观察到树突细胞成熟,T细胞透和M1巨细胞极化显著增加.
- 在一些H22模型小鼠中实现了完整的瘤回归,在VX2模型中抑制了瘤进展和转移.
结论:
- 阿斯菲尔联合提供HIF-1抑制剂和化疗提供了一种有前途的策略,以增强TACE对先进的HCC.
- 这种方法通过逆转瘤缺氧和免疫抑制来解决当前TACE治疗的关键局限性.
- 在EA@Asphere展示了改善高级HCC的临床结果的显著翻译潜力.
相关概念视频
Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Cancer Therapies
10.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.5K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
The Tumor Microenvironment
8.0K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
8.0K


